Data investigation

How Far You Can Walk

Peripheral artery disease stops people walking, and almost nothing improves it. A trial of 792 people measured actual walking distance, and the spread matters as much as the median.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Peripheral artery disease narrows the arteries in the legs, and its defining symptom is having to stop walking because of pain. Almost nothing improves it. A trial of 792 people measured the thing that matters, how far they could walk, and semaglutide beat placebo by 13%.[1] Then look at the spread: at least a quarter of the people on the drug walked less far than when they started.

Why this endpoint is different

Most of what we cover on this register is a number from a blood test or a scan, standing in for something a person would notice. This is not that. Participants walked on a treadmill at a fixed workload until leg pain stopped them, at the start and again a year later. The endpoint is the distance.

Peripheral artery disease affects an estimated 230 million people, and the treatments that improve how far someone can walk are few. That is why a functional result here counts for more than a laboratory one.

STRIDE: ratio of maximum walking distance at week 52 to baseline. A ratio above 1.0 means walking further.[1]
GroupMedian ratioInterquartile range
Semaglutide 1.0 mg1.210.95 – 1.55
Placebo1.080.86 – 1.36
Treatment ratio1.1395% CI 1.06–1.21, p = 0.0004

Two things the headline number hides

The first is that the placebo group improved too, by 8%. Repeated treadmill testing has a learning effect, and being in a trial changes how much people walk between visits. So the drug’s own contribution is the 13% difference, not the 21% improvement.

The second is in the interquartile range: the semaglutide group’s runs from 0.95 to 1.55. A ratio below 1.0 means walking a shorter distance than at baseline. At least a quarter of participants taking the drug were worse off at 52 weeks on the measure the trial was built around.

This is not a flaw in the trial. It is what progressive vascular disease looks like, and the placebo group’s lower quartile is worse still, at 0.86. But a median improving while a substantial minority declines is a different picture from “semaglutide improves walking distance,” and it is the picture someone deciding about treatment should have.

The middle of the group walked further. At least a quarter of them walked less.

Safety, and what the trial did not ask

Treatment-related serious adverse events were uncommon and slightly more frequent on placebo: six events in five participants on semaglutide against nine in six on placebo. There were no treatment-related deaths. For a 52-week trial in people with a median age of 68 and established vascular disease, that is a reassuring safety picture.

  • The dose was 1.0 mg, the type 2 diabetes strength, not the 2.4 mg used for weight management.
  • Everyone had type 2 diabetes. The authors explicitly call for studies in people with peripheral artery disease who do not, which is a large group; which US indications already apply to them is a separate question.
  • Three-quarters were men, and the median age was 68.
  • Nothing here addresses amputation, revascularization or survival, the outcomes that define how this disease ends. On amputation, the nearest evidence is a cohort of people with diabetic foot ulcers, and it shows an association only.
  • Funded by Novo Nordisk.

The authors also note that the mechanism is unclear. Whether the benefit comes from weight loss, from improved blood sugar, from effects on the blood vessels themselves, or from something else is unresolved. The broader pattern we have documented is that these drugs’ vascular benefits do not track weight loss.

What it means for someone with claudication

Trial participants had to be able to walk more than 200 meters to enroll (Fontaine stage IIa, the milder end of symptomatic disease). Someone whose walking is more limited than that was not studied.

Within that group, this is real evidence of a functional benefit, in a condition that has very little such evidence. It is a modest benefit, it is not universal, and it sits alongside supervised exercise therapy, which remains the best-established treatment for claudication and was not what this trial compared against.

Frequently Asked Questions

In STRIDE, people with type 2 diabetes and symptomatic peripheral artery disease walked 13% further than those on placebo after 52 weeks, measured on a treadmill. That is a functional benefit rather than a laboratory one, in a condition with few treatments.
The semaglutide group's walking distance improved by a median of 21% and the placebo group's by 8%, so the drug's own contribution is the 13% difference. Repeated treadmill testing and trial participation both improve walking on their own.
No. The semaglutide group's interquartile range runs from 0.95 to 1.55, meaning at least a quarter of people taking the drug walked a shorter distance at 52 weeks than at baseline. The placebo group's lower quartile was worse still.
It has not been tested. Everyone in the trial had type 2 diabetes, and the authors specifically call for studies in people who do not.
Not addressed. The trial measured walking distance over 52 weeks and does not speak to the outcomes that define how this disease progresses.

References

  1. 1.Bonaca MP, Catarig AM, Houlind K, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial The Lancet. 2025. PMID: 40169145.

Lifestyle Plus the Drug

Across 98,261 veterans with type 2 diabetes, taking a GLP-1 and keeping six to eight healthy habits was associated with 43% fewer cardiovascular events than three or fewer habits and no drug. The two figures people will compare cannot be compared.

5 min read

Semaglutide and Peripheral Artery Disease: The Label, the Options and Coverage

STRIDE showed semaglutide 1 mg improved walking distance in type 2 diabetes with PAD, and Novo Nordisk filed for a US label change in 2025. Ozempic's label still lists no PAD use, but PAD already counts as cardiovascular disease on the Ozempic and Wegovy labels.

7 min read

Muscle Loss: Drug Versus Dieting

Across 20 trials in 15,782 people, lean mass made up the same fraction of weight lost on incretin drugs as on dieting (p=0.42). Adding resistance training cut it from about a quarter to 17.5%.

6 min read

Exercise Plus a GLP-1: What Each One Actually Changes

In a four-arm randomized trial, the drug alone produced no improvement in physical fitness. Exercise did, with or without the drug, and the strength result needs reading carefully.

6 min read

Metformin vs GLP-1 for Longevity: The TAME Trial Has Not Started

No trial shows metformin extends life in people without diabetes. TAME, the metformin aging trial, has no registry record and was still unfunded at last report. Semaglutide has randomized outcome data, but only in people already at high risk.

9 min read

Ozempic Butt: What Large Weight Loss Changes in the Buttocks

No trial has measured buttock shape on semaglutide or tirzepatide. What changes is gluteal fat, some gluteal muscle and skin that does not retract, the same as with any large weight loss. What the DXA and MRI data show, what resistance training keeps, and what surgery can do.

11 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.2

HealthRX

Compounded semaglutide at $165/month after a $99 first month

8.2

bmiMD

Starting below a standard dose, with microdose tiers

9.0

YourEra

Semaglutide at $99/month, well below the typical price

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →